Methamphetamine Isomer Pharmacology in Humans

ConditionMethamphetamine

Trial statusNot yet recruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age21-64

SponsorUniversity of Wisconsin, Madison

About this trial

This study is being done to understand the metabolism and impairment profile of methamphetamine (meth). Meth exists as two chemical structures that are mirror images of each other: R-meth and S-meth. S-meth is a strong central nervous system stimulant and used to treat attention deficit disorder (ADD). R-meth is not a strong central nervous system stimulant and is available over-the-counter in nasal decongestant sprays.17 healthy participants will be enrolled for 3 study visits and on study for up to 12 weeks.

Eligibility criteria

Qualifiers

Good mental health as determined by self-reported responses to the Psychopathology Screener

Absence of any major cardiac, neurologic, psychiatric, oncologic, endocrine, metabolic, renal, or hepatic disease as determined by self-reported responses to the Medical History Screener

English-speaking (able to provide consent and complete questionnaires)

Written Informed Consent

Disqualifiers

Any serious prior adverse response to sympathomimetic agents or amphetamine analogs

History of or current substance use disorder as determined by self-reported responses to the Internalizing, Externalizing, and Substance Use Disorder Screener

Pregnancy or lactation (pregnancy test, if needed)

Use of medications that may impact cognition or metabolism (e.g., mood stabilizers, sedatives)

Trial design

Treatments tested in this trial

S-(+)-methamphetamine
R-(-)-methamphetamine
1:1 racemic mixture of two isomers

Treatment groups

17 Participants

are divided into 3 treatment groups

Sponsors and collaborators

University of Wisconsin, Madison

Lead sponsor

U.S. Department of Justice

Collaborator

Source ClinicalTrials.gov